NCT06718569Recruiting
Pain in Inflammatory Joint Diseases
Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 2 Dec 2024
- Start date
- 11 Nov 2025
- Primary completion date
- Nov 2027
- Lead sponsor
- Diakonhjemmet Hospital
- Diseases
- Psoriasis, Psoriatic arthritis, Rheumatoid arthritis
- NCT number
- NCT06718569
What you commit to
- Study type: Observational
- Planned participants: 350
- From 11 Nov 2025 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- All patients who initiate or switch biological or targeted synthetic DMARDs
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Diakonhjemmet Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.